Meanwhile, the BSE Sensex was up 228 points, or 1.31% to 17,673.75

On BSE, 6.45 lakh shares were traded in the counter as against average daily volume of 5.68 lakh shares in the past one quarter.

The stock hit a high of Rs 187.45 and a low of Rs 180 so far during the day. The stock had hit a 52-week low of Rs 112.25 on 19 December 2011. The stock had hit a 52-week high of Rs 324.65 on 4 April 2011.

The stock outperformed the market over the past one month till 27 February 2012, rising 4.44% compared with the Sensex's 1.23% gain. The scrip had also outperformed the market in past one quarter, surging 18.31% as against Sensex's 11.15% gain.

The mid-cap pharmaceutical company has an equity capital of Rs 70.44 crore. Face value per share is Rs 10.

Reacting to the report of foreign currency convertible bonds (FCCB) repayment, an Orchid Chemicals & Pharmaceuticals spokesperson was reportedly quoted as saying that the company will inform if something about this nature happens.

In December 2011, Orchid Chemicals & Pharmaceuticals had tied up with a consortium of Indian banks to raise $100 million through external commercial borrowings towards redeeming outstanding FCCBs. The company had floated the FCCBs in 2007 with maturity in February 2012 to raise funds for capacity expansion among other purposes.

On a consolidated basis, Orchid Chemicals & Pharmaceuticals' reported net loss of Rs 11.07 crore in Q3 December 2011 compared with net profit of Rs 56.62 crore in Q3 December 2010. Net sales rose 4.2% to Rs 482.10 crore in Q3 December 2011 over Q3 December 2010.

Orchid Chemicals & Pharmaceuticals is a leading pharmaceutical company involved in the development, manufacture and marketing of diverse bulk activities, formulations and nutraceuticals.